Extended Data Fig. 8: MRD-negative patients with T3N0 or T4N0 disease do not derive benefit from ACT. | Nature Medicine

Extended Data Fig. 8: MRD-negative patients with T3N0 or T4N0 disease do not derive benefit from ACT.

From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Extended Data Fig. 8

a-b. Kaplan-Meier estimates for DFS stratified by adjuvant treatment (observation versus ACT) in MRD-negative patients with T30N0 (a) or T4N0 (b) colon cancer. *HR was adjusted by age, sex and ECOG performance status. Hazard ratios (HRs) and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. The analysis was landmarked at 2 months post-surgery. Median DFS and percent DFS at 24 months were estimated from the landmark time point. Abbreviations: ACT, adjuvant chemotherapy.

Back to article page